PMID- 32193712
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Mar 19
TI  - Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
PG  - 29
LID - 10.1007/s11864-020-0721-7 [doi]
AB  - The treatment of advanced melanoma has undergone a dramatic transformation over 
      the last decade with the advent of targeted and immunomodulatory therapies. This 
      transition from cytotoxic chemotherapy has yielded improvements in both survival 
      and quality of life; yet despite their therapeutic advantages, these treatments 
      have been associated with a diverse range of cutaneous adverse events (AEs). 
      These range from relatively benign eczematous conditions to more severe 
      inflammatory and bullous disorders, and can include induction of second 
      malignancies. AEs can result in serious morbidity and risk of mortality if not 
      recognised and managed early. As a consequence of their novelty, and rapid 
      uptake, these agents have been subject to intense scrutiny and there is a general 
      understanding that cutaneous AEs should be anticipated in treatment plans. 
      Dermatologists should be integrated into management teams to assist in the 
      development of treatment protocols for anticipated common AEs and to provide 
      expert management of more severe, rare or unusual AEs. Our experience has shown a 
      reduction in treatment interruptions, more rapid recognition of unusual AEs and 
      improved management pathways for patients suffering cutaneous AEs.
FAU - Gnanendran, Subashini Sharon
AU  - Gnanendran SS
AD  - Dermatology Department, The Canberra Hospital, Australian National University, 
      Level 2, Building 6, Canberra, Australian Capital Territory, Australia.
AD  - ANU Medical School, Australian National University, Acton, Canberra, ACT, 2600, 
      Australia.
FAU - Turner, Lauren Maree
AU  - Turner LM
AD  - ANU Medical School, Australian National University, Acton, Canberra, ACT, 2600, 
      Australia.
FAU - Miller, James Austin
AU  - Miller JA
AD  - ANU Medical School, Australian National University, Acton, Canberra, ACT, 2600, 
      Australia. James.Miller@anu.edu.au.
FAU - Hwang, Shelley Ji Eun
AU  - Hwang SJE
AD  - Dermatology Department, The Canberra Hospital, Australian National University, 
      Level 2, Building 6, Canberra, Australian Capital Territory, Australia.
AD  - Sydney Medical School, University of Sydney, Camperdown, New South Wales, 
      Australia.
FAU - Miller, Andrew Charles
AU  - Miller AC
AD  - Dermatology Department, The Canberra Hospital, Australian National University, 
      Level 2, Building 6, Canberra, Australian Capital Territory, Australia.
AD  - ANU Medical School, Australian National University, Acton, Canberra, ACT, 2600, 
      Australia.
AD  - ACT Dermatology, 6/5 McKay Gardens, Turner, ACT, 2612, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200319
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Disease Management
MH  - Disease Susceptibility
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*adverse effects/therapeutic use
MH  - Molecular Targeted Therapy/adverse effects/methods
MH  - Neoplasms/complications/drug therapy/etiology
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
MH  - Skin Diseases/diagnosis/*etiology/therapy
OTO - NOTNLM
OT  - Adverse event
OT  - Anti-PD-1
OT  - Anti-programmed cell death protein 1 inhibitor
OT  - BRAF
OT  - Complication
OT  - Cutaneous
OT  - Dermatological
OT  - Dermatology
OT  - Immune therapy
OT  - Immunotherapy
OT  - Melanoma
OT  - Melanoma treatment
OT  - PD1
EDAT- 2020/03/21 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/03/21 06:00
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
AID - 10.1007/s11864-020-0721-7 [pii]
AID - 10.1007/s11864-020-0721-7 [doi]
PST - epublish
SO  - Curr Treat Options Oncol. 2020 Mar 19;21(4):29. doi: 10.1007/s11864-020-0721-7.